Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Status:
Terminated
Trial end date:
2019-12-14
Target enrollment:
Participant gender:
Summary
Phase 3 multicenter study to be conducted in up to 90 qualified participating sites globally
to assess the efficacy and safety of Reltecimod vs placebo in patients with sepsis-associated
Stage 2/3 AKI.